Last reviewed · How we verify

NCT06269887

Dominant Non-Dominant Upper Extremity in Gender

Completed Last updated 13 June 2024
What this trial tests

trial in Upper Extremity Problem in 213 participants. Completed in 30 March 2024.

Timeline
7 November 2023
Primary endpoint
15 March 2024
30 March 2024

Quick facts

Lead sponsorKarabuk University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment213
Start date7 November 2023
Primary completion15 March 2024
Estimated completion30 March 2024
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Karabuk University

Who can join

Adults 18 to 25, any sex, with Upper Extremity Problem or Gender Issues. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are strength and functional differences between non-dominant and dominant extremities. This is important in the hand and extremity rehabilitation process. This situation also differs between genders. Comparison of the dominant and non-dominant limb can provide important clinical or rehabilitation field-related information. It is reported in the literature that manual dexterity, grip strength and joint position sense may differ between extremities. However, the relationship between this situation and the difference between genders has not been explained. It is thought that examining this difference can be extremely useful in determining achievable goals in hand rehabilitation and in customizing care for different groups.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Upper Extremity Problem

Currently open trials in the same condition.

Other Karabuk University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06269887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing